Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies

site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
vertical-expand : a:0:{}
caf_enhance : 0
Drug Category : Array
Conference Category : Array
Lead Author : J Foley, et al.
Published Date : 18/09/2024
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2024/09/P1516-TG-Octave-Poster-ECTRIMS-2024_FINAL.pdf
Download Text :
Popup Confirmation? :
astra-migrate-meta-layouts : set
Scroll to Top